A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Summary

This is a multi-national, phase II, single arm study to explore the safety/efficacy and potential biomarkers on sunitinib 2/1 schedule for Asian patients with advanced renal cell carcinoma.

Timeline

Start

2015-08-12

Primary completion

2018-01-02

Completion

2018-01-02

Outcome

Outcome not reported

Stopped (Enrollment): “In most sites had difficult to recruitting subjects.”

Drugs

Indications